1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. AMAO BIOS
  6. News
  7. Summary
    AMAR   US02301P2056

AMAO BIOS

(AMAR)
End-of-day quote OTC Markets  -  2022-06-30
0.2894 USD   -0.03%
06/27Ainos Announces Positive Results from Preclinical Studies of Its Low-Dose Oral Interferon Formulation Against Covid-19
CI
06/27AINOS : Announces Positive Results from Preclinical Studies of Its Low-dose Oral Interferon Formulation Against COVID-19
PU
06/24AINOS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

AINOS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events, Financial Statements and Exhibits (form 8-K)

04/15/2022 | 01:08pm EDT

Item 1.01 Entry Into A Material Definitive Agreement.

Reference is made to that certain Convertible Note Purchase Agreement dated as of April 11, 2022 (the "Agreement") by and between Ainos, Inc., a Texas corporation (the "Company") and ASE Test, Inc. (collectively the "Purchaser"). The Purchaser is a member of the board of directors of the Company's controlling shareholder, Ainos, Inc., a Cayman Islands corporation.

Pursuant to the Agreement the Purchaser paid a total of $500,000 U.S.D. (the "Principal Amount") to the Company in exchange for a Convertible Promissory Note issued by the Company in the Principal Amount (the "Convertible Note").

The Principal Amount of the Convertible Note is payable in cash on March 30, 2027, although the Company may prepay the Convertible Note in whole or in part without penalty. The Convertible Note is non-interest bearing. If not earlier repaid, the Convertible Note will be converted into shares of common stock, $0.01 par value per share of the Company, or such other securities or property for which the Convertible Note may become convertible, immediately prior to the closing of any public offering of the Company's common stock as result of which the Company's common stock will be listed on a U.S. stock exchange. The conversion price, subject to certain adjustments described in Section 2(b) of the Convertible Note, will be eighty percent (80%) of the initial public offering price of the offering.

The foregoing description of the Agreement and Convertible Note are not complete and are qualified in their entirety by the text of the Agreement and the Convertible Note, forms of which are attached as Exhibit 2.1 and 10.1, respectively and incorporated herein by this reference.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The matters set forth under Sections 1.01 and 8.01 of this report are incorporated herein by this reference.


Item 8.01 Other Events


Reference is made to that certain Convertible Note Purchase Agreement dated as of March 31, 2022 (the "Agreement") by and between Ainos, Inc., a Texas corporation (the "Company") and Yun-Han Liao (collectively the "Purchaser"). The Purchaser is the daughter of We Hui-Lan, the Company's Chief Financial Officer.

Pursuant to the Agreement the Purchaser paid a total of $50,000 U.S.D. (the "Principal Amount") to the Company in exchange for a Convertible Promissory Note issued by the Company in the Principal Amount (the "Convertible Note").

The Principal Amount of the Convertible Note is payable in cash on March 30, 2027, although the Company may prepay the Convertible Note in whole or in part without penalty. The Convertible Note is non-interest bearing. If not earlier repaid, the Convertible Note will be converted into shares of common stock, $0.01 par value per share of the Company, or such other securities or property for which the Convertible Note may become convertible, immediately prior to the closing of any public offering of the Company's common stock as result of which the Company's common stock will be listed on a U.S. stock exchange. The conversion price, subject to certain adjustments described in Section 2(b) of the Convertible Note, will be eighty percent (80%) of the initial public offering price of the offering.

The foregoing description of the Agreement and Convertible Note are not complete and are qualified in their entirety by the text of the Agreement and the Convertible Note, forms of which are attached as Exhibit 2.1 and 10.1, respectively and incorporated herein by this reference.




2

Item 9.01 Financial Statements and Exhibits.

The following exhibits are filed as part of this report:



(d) Exhibits



Exhibit No.   Description

  2.1           Form of Convertible Note Purchase Agreement

10.1 Form of Convertible Promissory Note

© Edgar Online, source Glimpses

All news about AMAO BIOS
06/27Ainos Announces Positive Results from Preclinical Studies of Its Low-Dose Oral Interfer..
CI
06/27AINOS : Announces Positive Results from Preclinical Studies of Its Low-dose Oral Interfero..
PU
06/24AINOS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits..
AQ
06/21AINOS : COVID-19 Antigen Self-Test Receives Approval for Sale in Taiwan
PU
06/17AINOS, INC. Change in Directors or Principal Officers (form 8-K/A)
AQ
06/16AINOS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
06/16Ainos, Inc. Announces Executive Changes
CI
05/16AINOS, INC. Management's Discussion and Analysis of Financial Condition and Results of..
AQ
05/16Ainos, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/15AINOS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial O..
AQ
More news
Financials (USD)
Sales 2021 0,59 M - -
Net income 2021 -3,89 M - -
Net Debt 2021 1,87 M - -
P/E ratio 2021 -24,5x
Yield 2021 -
Capitalization 41,8 M 41,8 M -
EV / Sales 2020 478x
EV / Sales 2021 204x
Nbr of Employees 35
Free-Float 38,6%
Chart AMAO BIOS
Duration : Period :
AMAO BIOS Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Chun-Hsien Tsai Chairman, President & Chief Executive Officer
Hui-Lan Wu Chief Financial Officer
Lawrence K. Lin Executive Vice President-Operations
Wen-Han Chang Independent Director
Yao Chung Chiang Independent Director
Sector and Competitors
1st jan.Capi. (M$)
AMAO BIOS-65.55%42
GILEAD SCIENCES, INC.-14.12%78 219
VERTEX PHARMACEUTICALS30.84%73 484
REGENERON PHARMACEUTICALS, INC.-5.72%64 152
WUXI APPTEC CO., LTD.-13.31%44 566
BIONTECH SE-38.91%38 276